Teva’s share price dipped nearly 10% after it published its year-end financial results and guidance for 2023 last week, leaving the market to pick the bones out of the company’s base business and planned strategic update, set to be revealed midyear by new company CEO Richard Francis.
Former Biogen and Sandoz exec Francis told investors during the company’s 8 February earnings call that Teva hopes 2023 may be the year it
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?